% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Manzella:294417,
      author       = {G. Manzella and L. D. Schreck and W. B. Breunis and J.
                      Molenaar and H. Merks and F. G. Barr and W. Sun and M.
                      Römmele and L. Zhang and J. Tchinda and Q. A. Ngo and P.
                      Bode and O. Delattre and D. Surdez and B. Rekhi and F. K.
                      Niggli and B. W. Schäfer and M. Wachtel},
      title        = {{P}henotypic profiling with a living biobank of primary
                      rhabdomyosarcoma unravels disease heterogeneity and {AKT}
                      sensitivity.},
      journal      = {Nature Communications},
      volume       = {11},
      number       = {1},
      issn         = {2041-1723},
      address      = {[London]},
      publisher    = {Nature Publishing Group UK},
      reportid     = {DKFZ-2024-02246},
      pages        = {4629},
      year         = {2020},
      abstract     = {Cancer therapy is currently shifting from broadly used
                      cytotoxic drugs to patient-specific precision therapies.
                      Druggable driver oncogenes, identified by molecular
                      analyses, are present in only a subset of patients.
                      Functional profiling of primary tumor cells could circumvent
                      these limitations, but suitable platforms are unavailable
                      for most cancer entities. Here, we describe an in vitro drug
                      profiling platform for rhabdomyosarcoma (RMS), using a
                      living biobank composed of twenty RMS patient-derived
                      xenografts (PDX) for high-throughput drug testing. Optimized
                      in vitro conditions preserve phenotypic and molecular
                      characteristics of primary PDX cells and are compatible with
                      propagation of cells directly isolated from patient tumors.
                      Besides a heterogeneous spectrum of responses of largely
                      patient-specific vulnerabilities, profiling with a large
                      drug library reveals a strong sensitivity towards AKT
                      inhibitors in a subgroup of RMS. Overall, our study
                      highlights the feasibility of in vitro drug profiling of
                      primary RMS for patient-specific treatment selection in a
                      co-clinical setting.},
      keywords     = {Animals / Antineoplastic Agents: pharmacology / Biological
                      Specimen Banks / Drug Screening Assays, Antitumor: methods /
                      Gene Expression Profiling / Humans / Phenotype / Protein
                      Kinase Inhibitors / Proto-Oncogene Proteins c-akt:
                      antagonists $\&$ inhibitors / Proto-Oncogene Proteins c-akt:
                      genetics / Proto-Oncogene Proteins c-akt: metabolism /
                      Rhabdomyosarcoma: drug therapy / Rhabdomyosarcoma: genetics
                      / Rhabdomyosarcoma: metabolism / Tumor Cells, Cultured: drug
                      effects / Xenograft Model Antitumor Assays / Antineoplastic
                      Agents (NLM Chemicals) / Protein Kinase Inhibitors (NLM
                      Chemicals) / Proto-Oncogene Proteins c-akt (NLM Chemicals)},
      ddc          = {500},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32934208},
      pmc          = {pmc:PMC7492191},
      doi          = {10.1038/s41467-020-18388-7},
      url          = {https://inrepo02.dkfz.de/record/294417},
}